Clinical Trials
151 trialsTargeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
National Cancer Institute (NCI)
AndroMETa-CRC
AbbVie
Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory
Northwestern University
PARERE
Gruppo Oncologico del Nord-Ovest
A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation
Amgen
Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)
National Cancer Institute (NCI)
Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer
Australasian Gastro-Intestinal Trials Group
Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer
M.D. Anderson Cancer Center
Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)
Gruppo Oncologico del Nord-Ovest
A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma
Memorial Sloan Kettering Cancer Center
Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC
University of Wisconsin, Madison
BBOpCo
Duke University
Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer
M.D. Anderson Cancer Center
Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver
National Institutes of Health Clinical Center (CC)
NIPAVect
Emory University
HAITI
Gruppo Oncologico del Nord-Ovest
VICTORIA
National Cancer Institute, Naples
TRIFLUOX-DP
UNICANCER
Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC
M.D. Anderson Cancer Center
Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer
Memorial Sloan Kettering Cancer Center
89Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in HNSCC
Stanford University
PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC
UNC Lineberger Comprehensive Cancer Center
SAMCO
Federation Francophone de Cancerologie Digestive
OPTIPRIME
Federation Francophone de Cancerologie Digestive
A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer
Blokhin's Russian Cancer Research Center
PANIRINOX
UNICANCER
Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab
Ohio State University Comprehensive Cancer Center
Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer
M.D. Anderson Cancer Center
SULTAN
UNICANCER
Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer
Academic and Community Cancer Research United
Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two Study
Al-Azhar University
Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab
NantBioScience, Inc.
Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
Academic and Community Cancer Research United
Liquid-DRER2
Matteo's Friends
VELO
University of Campania Luigi Vanvitelli
DRUP
The Netherlands Cancer Institute
A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
Sumitomo Pharma America, Inc.
Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer
University of Nebraska
A Phase 2 Basket Trial in Which Patients With Advanced Solid Tumors Carrying the KRAS G12C mUtation Receive Treatment With a Combination of Sotorasib and Panitumumab
Korea University Anam Hospital
FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer
Criterium, Inc.
VOLFI
AIO-Studien-gGmbH
PanaMa
AIO-Studien-gGmbH
Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer
M.D. Anderson Cancer Center
PACER
National Cancer Institute, Naples
PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors
Amgen
Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer
Amgen
PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)
Amgen
CHRONOS
Fondazione del Piemonte per l'Oncologia
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
Radiation Therapy Oncology Group
A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer
University Health Network, Toronto